
DBV Technologies S.A. DBVT
$ 21.59
-0.12%
Quarterly report 2025-Q2
added 07-29-2025
DBV Technologies S.A. Deferred Revenue 2011-2026 | DBVT
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue DBV Technologies S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 3.2 M | 4.36 M | 2.79 M | 3.25 M | 791 K | 1.05 M | 794 K | 127 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.36 M | 127 K | 2.05 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
55.7 M | $ 18.33 | -0.92 % | $ 2.7 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
2.4 M | $ 72.81 | 5.02 % | $ 9.74 B | ||
|
I-Mab
IMAB
|
563 K | - | - | $ 866 M | ||
|
Aytu BioScience
AYTU
|
339 K | $ 2.72 | 4.62 % | $ 17.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
726 K | $ 2.99 | 8.55 % | $ 168 M | ||
|
Biogen
BIIB
|
55.7 M | $ 177.96 | -1.07 % | $ 25.9 B | ||
|
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | ||
|
Alterity Therapeutics Limited
ATHE
|
33.3 K | $ 3.12 | -1.74 % | $ 7.51 B | ||
|
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K | ||
|
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
3.74 M | $ 1.4 | -0.71 % | $ 262 M | ||
|
Ascendis Pharma A/S
ASND
|
363 K | $ 223.74 | -1.05 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
85.7 K | - | -11.43 % | $ 502 K | ||
|
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 4.13 | 2.92 % | $ 8.99 B | ||
|
Aravive
ARAV
|
4.41 M | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
300 M | $ 110.82 | -2.58 % | $ 27.2 B | ||
|
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | ||
|
Adaptimmune Therapeutics plc
ADAP
|
29 M | - | -15.15 % | $ 60.3 M | ||
|
Brickell Biotech
BBI
|
1.8 M | - | -5.38 % | $ 6.06 M | ||
|
Compugen Ltd.
CGEN
|
9.63 M | $ 1.85 | 0.27 % | $ 166 M | ||
|
AIkido Pharma
AIKI
|
240 K | - | 1.93 % | $ 17.4 M | ||
|
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
2.91 M | - | 2.71 % | $ 14 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
1.42 M | $ 6.68 | 1.52 % | $ 1.38 B | ||
|
Alpine Immune Sciences
ALPN
|
35.6 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | ||
|
Beam Therapeutics
BEAM
|
109 M | $ 28.17 | 1.99 % | $ 2.32 B | ||
|
BeiGene, Ltd.
BGNE
|
187 M | - | 0.49 % | $ 251 B |